DOCSLIB.ORG

Anti-Inflammatory Pro-Resolving Mediators with Therapeutic Potential

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Anti-Inflammatory Pro-Resolving Mediators with Therapeutic Potential European Review for Medical and Pharmacological Sciences 2020; 24: 7442-7453 Maresins: anti-inflammatory pro-resolving mediators with therapeutic potential Q.- F. LI1, H. HAO2, W.-S. TU1, N. GUO1, X.-Y. ZHOU3,4 1The First Clinical Medical College, Nanchang University, Nanchang, P.R. China 2Department of Pathology, Second Affiliated Hospital of Nanchang University, Nanchang, P.R. China 3Department of Pathophysiology, Medical College of Nanchang University, Nanchang, Jiangxi, P.R. China 4Jiangxi Province Key Laboratory of Tumor pathogenesis and Molecular Pathology, Nanchang, Jiangxi, P.R. China Qi-Fan Li and Hua Hao equally contributed to this paper Abstract. – Although inflammation is protec- nized as an important factor in chronic diseases tive of the body, uncontrolled acute inflammato- such as metabolic syndrome, cardiovascular dis- ry reactions may inflict tissue damage and lead ease, and nervous system diseases4-8, and it has to chronic inflammation. There is a fast-grow- therefore become a major public health concern. ing research interest in mechanisms that me- Anti-inflammatory mediators form a class of fac- diate regression of inflammation and actions of tors preventing further inflammation and tissue anti-inflammatory factors. Studies of inflamma- 9 tory and anti-inflammatory mechanisms have damage . The therapeutic use of anti-inflamma- uncovered roles for new lipid mediators, in- tory mediators may reduce inflammation-induced cluding lipoxins, resolvins, protectins, and ma- damage and have curative effects on the resulting resins, collectively referred to as specialized chronic diseases. pro-resolving mediators (SPM). Maresins have Fatty acids act as metabolic fuels for the recently been discovered and are biosynthe- human body and form an important part of the sized from docosahexaenoic acid (DHA) by mac- 10 rophages and display strong anti-inflammatory cell membrane . Besides these functions, fatty and pro-resolving activities. Here, we summa- acids affect human health by acting as signal- rize the actions and mechanisms of maresins in ing molecules11. They not only have an impact different diseases and suggest possible thera- on the health of cardiovascular diseases but peutic uses. also have impacts in a range of other diseases, Key Words: including metabolic and inflammatory diseas- 12 Inflammation, Lipid mediators, Maresins. es, and cancer . ω-6 Fatty acids (e.g., linoleic acid; LA) and ω-3 fat acids (e.g., α-linolenic acid; ALA) are essential fatty acids that can- not be synthesized by humans or other higher Introduction animals13. After a series of complex desatura- tion-and elongation reactions acting in concert Although inflammation is a predominantly to transform LA and ALA to their higher un- self-protective bodily response, acute excessive saturated derivatives: arachidonic acid (AA) levels of inflammation may cause great damage from LA, eicosapentaenoic acid (EPA) and to our health1. The inflammatory response in- docosahexaenoic acid (DHA) from ALA14,15. volves interactions between many different cell The conversion pathways are shown in Figure types and cytokines2. Typical symptoms accom- 1, and the produced derivatives will undergo panying inflammatory responses include fever, further biochemical processing in the body and redness, swelling, pain and loss of function3. are converted into molecules that affect metab- Today, excessive inflammation is widely recog- olism directly. 7442 Corresponding Author: Xiaoyan Zhou, Ph.D; e-mail: [email protected] Maresins: anti-inflammatory pro-resolving mediators with therapeutic potential Figure 1. The production of biosynthesis of pro-resolving lipid mediators. Abbreviation: 5/12/15-LOX, 5/12/15-Lipoxygenase; COX-2, Cyclooxygenase-2; RvD, resolving D series; RvE, resolving E series; MaR, maresin; PD1, Protectin D1; PDX, Protectin DX; LXA4, Lipoxin A4; LXB4, Lipoxin B4. SPMs are derived from essential fatty acids from the simplest ω-3 fatty acid, ALA, are es- and play crucial roles in orchestrating the reso- pecially abundant in e.g., fish oils, and play lution of tissue inflammation16. The new pro-re- important roles in organ function and health28. solving lipid mediators include separate families In humans, metabolites of PUFAs are known to of molecules: lipoxins, resolvins, protectins and trigger inflammation. However, prostaglandin E3 maresins, which are derived from AA and ome- and leukotriene B5 produced by ω-3 PUFAs are ga-3 polyunsaturated fatty acids17-20. Lipoxins and much less biologically active than the prosta- aspirin-triggered lipoxins, generated from AA, glandin E2 and leukotriene B4 produced by ω-6 reduce inflammation and promote resolution. In PUFAs 29. Furthermore, lipid mediators such as contrast, resolvins, maresins and protectins are resolvins and protectins produced by EPA and derived from omega-3 polyunsaturated fatty ac- DHA metabolism promote the regression of in- id21,22. Maresins are a class of 14S-dihydrox- flammation30. yl-containing molecules with conjugated triene Maresins form the third-largest family of double bonds, which are synthesized from DHA SPMs derived from DHA20. The biosynthesis of through an oxidative (e.g., lipoxygenase-relat- maresins occurs primarily in M2 macrophages ed) pathway during inflammation regression23. and is initiated by a reaction involving human In general, the biosynthesis of maresins occurs macrophage 12-lipoxygenase (12-LOX)31. The li- in M2 macrophages24. Abdulnour et al25 report poxygenation reaction involves insertion of an that maresin 1 is synthesized in the interaction of oxygen atom into DHA on the fourteenth carbon platelets with neutrophils. This review addresses atom. This generates 14S-HpDHA, which is fur- the contributing roles of maresins to the regres- ther transformed into 13S,14S-epoxide maresin, sion of inflammation and highlights their poten- followed by a conversion, performed by different tially beneficial roles in the resolution of various enzymes, e.g., maresin 1, maresin 2, and maresin diseases. conjugate in tissue regeneration (MCTR)32. Maresin 1 was the first discovered member Biosynthesis and Stereochemistry of the family of maresins33. By the action of Polyunsaturated fatty acids (PUFAs) play an 12-LOX, DHA was found to be converted to important role in the initiation, development and 14S-HpDHA 34. 12-LOX is a key enzyme in the regression of inflammation26,27. Two classes of synthesis of maresins35. When 12-LOX is absent PUFAs are distinguished: n-3 (ω-3) PUFAs and in macrophages, the production of 14S-HpDHA n-6 (ω-6) PUFAs15. DHA and EPA are derived is reduced by > 95%. By the action of 12-LOX, 7443 Q.-F. Li, H. Hao, W.-S. Tu, N. Guo, X.-Y. Zhou 14S-HpDHA is converted to 13S,14S-epoxy-ma- tion, oxidative stress and immune diseases. As resin. Next, by an epoxide-hydrolysis reaction, far as the current research proves, the cell actions the double bond in the 13S, 14S-epoxy-maresin is of maresins mainly promote the polarization and reconfigured to a Z/E configuration, yielding the phagocytosis of M2 macrophages41, inhibit the final product 7R, 14S-dihydroxydocosa-4Z, 8E, infiltration of neutrophils25, and induce Treg gen- 10E, 12Z, 16Z, 19Z-hexaenoic acid (maresin 1). eration42. Maresin 1 inhibits the differentiation of In addition, maresin 1 is produced by combined naive T cells into T-helper 1 (TH1) and T-help- actions of platelets and neutrophils25. Through er 17 (TH17) and promotes differentiation into the action of 12-LOX in platelets, DHA is con- Treg43. In various inflammatory environments, verted into 13S, 14S-epoxy-maresin, which is maresins inhibit the expression of pro-inflam- then transformed into maresin 1 by neutrophils. matory cytokines such as IL-6, TNF-α and IL- The substrates and initial steps for the biosyn- lβ by inhibiting TLR4/MAPK/NF-κB signaling thesis of maresin 2 are the same as for maresin pathway. Not only that, maresins can inhibit 1. The difference is that when DHA is converted the expression of TGF-β1, thereby inhibiting the to the intermediate 13S,14S-epoxy-maresin, it is phenotype transformation of fibroblasts by inhib- oxidized to 13R,14S-dihydroxy-docosahexaenoic iting the ERK/Smad signaling pathway. Maresins acid (13R, 14S-diHDHA) (maresin 2) by soluble increase the expression of oxidoreductase and epoxide hydrolase (sEH) within human macro- detoxification enzymes by activating the Nrf-2 phages36. MCTR is a conjugate in the process of signaling pathway, while reducing ROS genera- maresin-induced tissue regeneration, including tion by inhibiting the NF-κB signaling pathway44. MCTR1 (13R-glutathionyl, 14S-hydroxy-4Z, 7Z, By activating AMPK and PPARα, which can in- 9E, 11E, 13R, 14S, 16Z, 19Z-docosahexaenoic hibit endoplasmic reticulum (ER) stress, thereby acid), MCTR2 (13R-cysteinylglycinyl, 14S-hy- protecting the body. The molecular identifica- droxy-4Z, 7Z, 9E, 11E, 13R, 14S, 16Z, 19Z-do- tion of mareisns signal through its receptor has cosahexaenoic acid), MCTR3 (13R-cysteinyl, not yet been identified. The actions of maresins 14S-hydroxy-4Z, 7Z, 9E, 11E, 13R, 14S, 16Z, were shown in Figure 3. Inferred from current 19Z-docosahexaenoic acid)37. The biosynthesis of research, maresin 1 blocked transient receptor MCTRs (like that of maresins 1 and 2) is initiated potential V1-mediated currents in neurons45, acts by 12-LOX. The 13S, 14S-epoxy-maresin is con- as a ligand for Retinoid related orphan receptor α verted to MCTR1 by the catalysis of glutathione (RORα), inhibits TLR4 signaling. Chiang et al46 S-transferase MU 4 (GSTM4) and leukotriene has revealed that maresin 1 can activate LGR6, C4 synthase (LTC4S). MCTR1 is a precursor of a member of the glycoprotein hormone receptor MCTR2 and is converted to MCTR2 under the subfamily of rhodopsin-like GPCR, which ini- catalysis of gamma-glutamyl transferase (GGT). tiates cAMP and impedance change, as well as The biosynthesis of MCTR3 is based on MC- stimulates innate immune responses on PMN, TR2, with the catalysis of dipeptidases (DPEP), monocytes, and MΦ. Further research may reveal MCTR2 is converted to MCTR338. Conversion the receptors and mechanisms of maresins. relationship between DHA and maresin isomers is shown in Figure 2.
Load more

Recommended publications
  • Neuroprotection by Glial Metabotropic Glutamate Receptors Is Mediated by Transforming Growth Factor-␤
    The Journal of Neuroscience, December 1, 1998, 18(23):9594–9600 Neuroprotection by Glial Metabotropic Glutamate Receptors Is Mediated by Transforming Growth Factor-b V. Bruno,1 G. Battaglia,1 G. Casabona,1 A. Copani,2 F. Caciagli,3 and F. Nicoletti1,2 1Istituto Neurologico Mediterraneo Neuromed, 86077 Pozzilli, Italy, 2Institute of Pharmacology, School of Pharmacy, University of Catania, 95125 Catania, Italy, and 3Department of Pharmacological Sciences, University of Chieti, 66013 Chieti, Italy The medium collected from cultured astrocytes transiently ex- protective activity of DCG-IV or 4C3HPG, as well as the activity posed to the group-II metabotropic glutamate (mGlu) receptor of GM/DCG-IV or GM/4C3HPG; and (3) a transient exposure of 9 9 9 agonists (2S ,1 R ,2 R ,3 R )-2-(2,3-dicarboxycyclopropyl)glycine cultured astrocytes to either DCG-IV or 4C3HPG led to a de- (DCG-IV) or (S)-4-carboxy-3-hydroxyphenylglycine (4C3HPG) layed increase in both intracellular and extracellular levels of is neuroprotective when transferred to mixed cortical cultures TGFb. We therefore conclude that a transient activation of challenged with NMDA (Bruno et al., 1997). The following data group-II mGlu receptors (presumably mGlu3 receptors) in as- indicate that this particular form of neuroprotection is mediated trocytes leads to an increased formation and release of TGFb, by transforming growth factor-b (TGFb). (1) TGFb1 and -b2 which in turn protects neighbor neurons against excitotoxic were highly neuroprotective against NMDA toxicity, and their death. These results offer a new strategy for increasing the local action was less than additive with that produced by the medium production of neuroprotective factors in the CNS.
    [Show full text]
  • Eicosanoids in Carcinogenesis
    4open 2019, 2,9 © B.L.D.M. Brücher and I.S. Jamall, Published by EDP Sciences 2019 https://doi.org/10.1051/fopen/2018008 Special issue: Disruption of homeostasis-induced signaling and crosstalk in the carcinogenesis paradigm “Epistemology of the origin of cancer” Available online at: Guest Editor: Obul R. Bandapalli www.4open-sciences.org REVIEW ARTICLE Eicosanoids in carcinogenesis Björn L.D.M. Brücher1,2,3,*, Ijaz S. Jamall1,2,4 1 Theodor-Billroth-Academy®, Germany, USA 2 INCORE, International Consortium of Research Excellence of the Theodor-Billroth-Academy®, Germany, USA 3 Department of Surgery, Carl-Thiem-Klinikum, Cottbus, Germany 4 Risk-Based Decisions Inc., Sacramento, CA, USA Received 21 March 2018, Accepted 16 December 2018 Abstract- - Inflammation is the body’s reaction to pathogenic (biological or chemical) stimuli and covers a burgeoning list of compounds and pathways that act in concert to maintain the health of the organism. Eicosanoids and related fatty acid derivatives can be formed from arachidonic acid and other polyenoic fatty acids via the cyclooxygenase and lipoxygenase pathways generating a variety of pro- and anti-inflammatory mediators, such as prostaglandins, leukotrienes, lipoxins, resolvins and others. The cytochrome P450 pathway leads to the formation of hydroxy fatty acids, such as 20-hydroxyeicosatetraenoic acid, and epoxy eicosanoids. Free radical reactions induced by reactive oxygen and/or nitrogen free radical species lead to oxygenated lipids such as isoprostanes or isolevuglandins which also exhibit pro-inflammatory activities. Eicosanoids and their metabolites play fundamental endocrine, autocrine and paracrine roles in both physiological and pathological signaling in various diseases. These molecules induce various unsaturated fatty acid dependent signaling pathways that influence crosstalk, alter cell–cell interactions, and result in a wide spectrum of cellular dysfunctions including those of the tissue microenvironment.
    [Show full text]
  • A Novel Resolvin-Based Strategy for Limiting Acetaminophen Hepatotoxicity
    A Novel Resolvin-Based Strategy for Limiting Acetaminophen Hepatotoxicity The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Patel, Suraj J, Jay Luther, Stefan Bohr, Arvin Iracheta-Vellve, Matthew Li, Kevin R King, Raymond T Chung, and Martin L Yarmush. 2016. “A Novel Resolvin-Based Strategy for Limiting Acetaminophen Hepatotoxicity.” Clinical and Translational Gastroenterology 7 (3): e153. doi:10.1038/ctg.2016.13. http://dx.doi.org/10.1038/ctg.2016.13. Published Version doi:10.1038/ctg.2016.13 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:26860020 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Citation: Clinical and Translational Gastroenterology (2016) 7, e153; doi:10.1038/ctg.2016.13 & 2016 the American College of Gastroenterology All rights reserved 2155-384X/16 www.nature.com/ctg A Novel Resolvin-Based Strategy for Limiting Acetaminophen Hepatotoxicity Suraj J. Patel, MD, PhD1,2,5, Jay Luther, MD3,5, Stefan Bohr, MD1, Arvin Iracheta-Vellve, BS1, Matthew Li, PhD1, Kevin R. King, MD, PhD1, Raymond T. Chung, MD3 and Martin L. Yarmush, MD, PhD1,2,4 OBJECTIVES: Acetaminophen (APAP)-induced hepatotoxicity is a major cause of morbidity and mortality. The current pharmacologic treatment for APAP hepatotoxicity, N-acetyl cysteine (NAC), targets the initial metabolite-driven injury but does not directly affect the host inflammatory response.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,872,152 B2 Serhan Et Al
    US007872152B2 (12) United States Patent (10) Patent No.: US 7,872,152 B2 Serhan et al. (45) Date of Patent: Jan. 18, 2011 (54) USE OF DOCOSATRIENES, RESOLVINS AND (58) Field of Classification Search ....................... None THER STABLE ANALOGS IN THE See application file for complete search history. TREATMENT OF AIRWAY DISEASES AND (56) References Cited ASTHMA U.S. PATENT DOCUMENTS (75) Inventors: Charles N. Serhan, Needham, MA (US); Bruce D. Levy, West Roxbury, 4,201,211 A 5/1980 Chandrasekaran et al. MA (US) (Continued) (73) Assignee: The Brigham and Women's Hospital, FOREIGN PATENT DOCUMENTS Inc., Boston, MA (US) EP O736509 A2 10, 1996 (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (Continued) U.S.C. 154(b) by 198 days. OTHER PUBLICATIONS (21) Appl. No.: 11/836,460 Hong et al., Journal of Biological Chemistry 278(17) 14677-14687.* (22) Filed: Aug. 9, 2007 (Continued) Primary Examiner Karl J. Puttlitz (65) Prior Publication Data (74) Attorney, Agent, or Firm—Colin L. Fairman; Scott D. US 2008/OO96961 A1 Apr. 24, 2008 Rothenberge; Fulbright & Jaworski Related U.S. Application Data (57) ABSTRACT (63) Continuation of application No. 11/081,203, filed on The present invention is generally drawn to novel isolated Mar. 16, 2005, and a continuation-in-part of applica therapeutic agents, termed resolving, generated from the tion No. 10/639,714, filed on Aug. 12, 2003, now Pat. interaction between a dietary omega-3 polyunsaturated fatty No. 7,585,856. acid (PUFA) such as eicosapentaenoic acid (EPA) or docosa (60) Provisional application No.
    [Show full text]
  • Role of 17-HDHA in Obesity-Driven Inflammation Angelika
    Diabetes Page 2 of 38 Impaired local production of pro-resolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation Running title: Role of 17-HDHA in obesity-driven inflammation Angelika Neuhofer1,2, Maximilian Zeyda1,2, Daniel Mascher3, Bianca K. Itariu1,2, Incoronata Murano4, Lukas Leitner1,2, Eva E. Hochbrugger1,2, Peter Fraisl1,4, Saverio Cinti5,6, Charles N. Serhan7, Thomas M. Stulnig1,2 1Clinical Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Vienna, Austria, 2Christian Doppler-Laboratory for Cardio-Metabolic Immunotherapy, Medical University of Vienna, Vienna, Austria, 3pharm-analyt Labor GmbH, Baden, Austria, 4Flander Institute for Biotechnology and Katholieke Universiteit Leuven, Belgium, 5Department of Molecular Pathology and Innovative Therapies, University of Ancona (Politecnicadelle Marche), Ancona, Italy, 6The Adipose Organ Lab, IRCCS San Raffele Pisana, Rome, 00163, Italy, 7Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115 Corresponding author: Thomas M. Stulnig, Clinical Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria; phone +43 1 40400 61027; fax +43 1 40400 7790; e-mail: [email protected] Word count: 4394 Number of tables and figures: 7 figures and online supplemental material (1 supplemental figure and 2 supplemental tables) 1 Diabetes Publish Ahead of Print, published online January 24, 2013 Page 3 of 38 Diabetes ABSTRACT Obesity-induced chronic low-grade inflammation originates from adipose tissue and is crucial for obesity-driven metabolic deterioration including insulin resistance and type 2 diabetes.
    [Show full text]
  • Metabolites OH
    H OH metabolites OH Article 16HBE Cell Lipid Mediator Responses to Mono and Co-Infections with Respiratory Pathogens Daniel Schultz 1, Surabhi Surabhi 2 , Nicolas Stelling 2, Michael Rothe 3, KoInfekt Study 1 2 2, 1, Group y, Karen Methling , Sven Hammerschmidt , Nikolai Siemens * and Michael Lalk * 1 Institute of Biochemistry, University of Greifswald, 17487 Greifswald, Germany; [email protected] (D.S.); [email protected] (K.M.) 2 Department of Molecular Genetics and Infection Biology, University of Greifswald, 17487 Greifswald, Germany; [email protected] (S.S.); [email protected] (N.S.); [email protected] (S.H.) 3 Lipidomix, 13125 Berlin, Germany; [email protected] * Correspondence: [email protected] (N.S.); [email protected] (M.L.); Tel.: +49-3834-420-5711 (N.S.); +49-3834-420-4867 (M.L.) The members of the KoInfekt Study Group are listed in AppendixA. y Received: 26 January 2020; Accepted: 13 March 2020; Published: 18 March 2020 Abstract: Respiratory tract infections are a global health problem. The main causative agents of these infections are influenza A virus (IAV), Staphylococcus aureus (S. aureus), and Streptococcus pneumoniae (S. pneumoniae). Major research focuses on genetics and immune responses in these infections. Eicosanoids and other oxylipins are host-derived lipid mediators that play an important role in the activation and resolution of inflammation. In this study, we assess, for the first time, the different intracellular profiles of these bioactive lipid mediators during S. aureus LUG2012, S. pneumoniae TIGR4, IAV, and corresponding viral and bacterial co-infections of 16HBE cells.
    [Show full text]
  • An Imbalance Between Specialized Pro-Resolving Lipid Mediators and Pro-Inflammatory Leukotrienes Promotes Instability of Atherosclerotic Plaques
    ARTICLE Received 5 Feb 2016 | Accepted 10 Aug 2016 | Published 23 Sep 2016 DOI: 10.1038/ncomms12859 OPEN An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques Gabrielle Fredman1,2,*, Jason Hellmann3,*, Jonathan D. Proto1, George Kuriakose1, Romain A. Colas3, Bernhard Dorweiler4, E. Sander Connolly5, Robert Solomon5, David M. Jones6, Eric J. Heyer7, Matthew Spite3 & Ira Tabas1 Chronic unresolved inflammation plays a causal role in the development of advanced atherosclerosis, but the mechanisms that prevent resolution in atherosclerosis remain unclear. Here, we use targeted mass spectrometry to identify specialized pro-resolving lipid mediators (SPM) in histologically-defined stable and vulnerable regions of human carotid atherosclerotic plaques. The levels of SPMs, particularly resolvin D1 (RvD1), and the ratio of SPMs to pro-inflammatory leukotriene B4 (LTB4), are significantly decreased in the vulnerable regions. SPMs are also decreased in advanced plaques of fat-fed Ldlr À/ À mice. Adminis- tration of RvD1 to these mice during plaque progression restores the RvD1:LTB4 ratio to that of less advanced lesions and promotes plaque stability, including decreased lesional oxidative stress and necrosis, improved lesional efferocytosis, and thicker fibrous caps. These findings provide molecular support for the concept that defective inflammation resolution contributes to the formation of clinically dangerous plaques and offer a mechanistic rationale for SPM therapy to promote plaque stability. 1 Department of Anesthesiology, Perioperative and Pain Medicine, Departments of Medicine, Pathology & Cell Biology, and Physiology, Columbia University Medical Center, 630 West 168th Street, New York, New York 10032, USA. 2 The Department of Molecular and Cellular Physiology, Center for Cardiovascular Sciences, Albany Medical College, 47 New Scotland Avenue, Albany, New York 12208, USA.
    [Show full text]
  • Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back
    International Journal of Molecular Sciences Review Cannabis, the Endocannabinoid System and Immunity—The Journey from the Bedside to the Bench and Back Osnat Almogi-Hazan * and Reuven Or Laboratory of Immunotherapy and Bone Marrow Transplantation, Hadassah Medical Center, The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel; [email protected] * Correspondence: [email protected] Received: 21 May 2020; Accepted: 19 June 2020; Published: 23 June 2020 Abstract: The Cannabis plant contains numerous components, including cannabinoids and other active molecules. The phyto-cannabinoid activity is mediated by the endocannabinoid system. Cannabinoids affect the nervous system and play significant roles in the regulation of the immune system. While Cannabis is not yet registered as a drug, the potential of cannabinoid-based medicines for the treatment of various conditions has led many countries to authorize their clinical use. However, the data from basic and medical research dedicated to medical Cannabis is currently limited. A variety of pathological conditions involve dysregulation of the immune system. For example, in cancer, immune surveillance and cancer immuno-editing result in immune tolerance. On the other hand, in autoimmune diseases increased immune activity causes tissue damage. Immuno-modulating therapies can regulate the immune system and therefore the immune-regulatory properties of cannabinoids, suggest their use in the therapy of immune related disorders. In this contemporary review, we discuss the roles of the endocannabinoid system in immunity and explore the emerging data about the effects of cannabinoids on the immune response in different pathologies. In addition, we discuss the complexities of using cannabinoid-based treatments in each of these conditions.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION 17(R)-Resolvin D1 Item No. 13060 CAS Registry No.: 528583-91-7 Formal Name: 7S,8R,17R-trihydroxy- 4Z,9E,11E,13Z,15E19Z- HO docosahexaenoic acid Synonyms: Aspirin-triggered Resolvin D1, AT-RvD1, 17-epi-Resolvin D1, 17(R)-RvD1 COOH OH MF: C22H32O5 FW: 376.5 Purity: ≥95% Stability: ≥1 year at -80°C Supplied as: A solution in ethanol OH Special Conditions: Light Sensitive UV/Vis.: λmax: 302 nm Laboratory Procedures For long term storage, we suggest that 17(R)-resolvin D1 (17(R)-RvD1) be stored as supplied at -80°C. It should be stable for at least one year. 17(R)-RvD1 is supplied as a solution in ethanol. To change the solvent, simply evaporate the ethanol under a gentle stream of nitrogen and immediately add the solvent of choice. It is recommended that this product be stored and handled in an ethanol solution. Resolvins can isomerize and degrade when put into freeze thaw conditions and/or in solvents such as DMF or DMSO. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. If an organic solvent-free solution of 17(R)-RvD1 is needed, it can be prepared by evaporating the ethanol and directly dissolving the neat oil in aqueous buffers. The solubility of 17(R)-RvD1 in PBS, pH 7.2, is approximately 0.05 mg/ml. Aqueous solutions of 17(R)-RvD1 should be discarded immediately after use.
    [Show full text]
  • Maresin 1 Promotes Inflammatory Resolution, Neuroprotection, and Functional Neurological Recovery After Spinal Cord Injury
    The Journal of Neuroscience, November 29, 2017 • 37(48):11731–11743 • 11731 Development/Plasticity/Repair Maresin 1 Promotes Inflammatory Resolution, Neuroprotection, and Functional Neurological Recovery After Spinal Cord Injury Isaac Francos-Quijorna,1 XEva Santos-Nogueira,1 Karsten Gronert,2 Aaron B. Sullivan,2 XMarcel A. Kopp,3 X Benedikt Brommer,3,4 Samuel David,5 XJan M. Schwab,3,6,7 and XRuben Lo´pez-Vales1 1Departament de Biologia Cel⅐lular, Fisiologia i Immunologia, Institut de Neurociencies, Centro de Investigacio’n Biome’dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Universitat Autonoma de Barcelona, 08193 Bellaterra, Catalonia, Spain, 2Vision Science Program, School of Optometry, University of California Berkeley, Berkeley, California 94598, 3Spinal Cord Alliance Berlin (SCAB) and Department of Neurology and Experimental Neurology, Charite´ Campus Mitte, Clinical and Experimental Spinal Cord Injury Research Laboratory (Neuroparaplegiology), Charite´-Universita¨tsmedizin Berlin, 10117 Berlin, Germany, 4F.M. Kirby Neurobiology Center, Boston Children’s Hospital, and Department of Neurology, Harvard Medical School, Boston, Massachusetts 02115, 5Centre for Research in Neuroscience, The Research Institute of the McGill University Health Centre, H3G1A4 Montreal, Canada, and 6Department of Neurology, Spinal Cord Injury Division, and 7Department of Neuroscience and Center for Brain and Spinal Cord Repair, Department of Physical Medicine and Rehabilitation, The Neurological Institute, The Ohio State University, Wexner Medical Centre, Columbus, Ohio 43210 Resolution of inflammation is defective after spinal cord injury (SCI), which impairs tissue integrity and remodeling and leads to functional deficits. Effective pharmacological treatments for SCI are not currently available. Maresin 1 (MaR1) is a highly conserved specialized proresolving mediator (SPM) hosting potent anti-inflammatory and proresolving properties with potent tissue regenerative actions.
    [Show full text]
  • Caffeine Induces Neurobehavioral Effects Through Modulating Neurotransmitters
    Saudi Pharmaceutical Journal 28 (2020) 445–451 Contents lists available at ScienceDirect Saudi Pharmaceutical Journal journal homepage: www.sciencedirect.com Review Caffeine induces neurobehavioral effects through modulating neurotransmitters Fawaz Alasmari Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia article info abstract Article history: Evidence demonstrates that chronic caffeine exposure, primarily through consumption of coffee or tea, Received 19 November 2019 leads to increased alertness and anxiety. Preclinical and clinical studies showed that caffeine induced Accepted 12 February 2020 beneficial effects on mood and cognition. Other studies using molecular techniques have reported that Available online 17 February 2020 caffeine exhibited neuroprotective effects in animal models by protecting dopaminergic neurons. Moreover, caffeine interacts with dopaminergic system, which leads to improvements in neurobehavioral Keywords: measures in animal models of depression or attention deficit hyperactivity disorder (ADHD). Caffeine Glutamatergic receptors have been found to be involved on the neurobiological effects of caffeine. Neurobehavioral effects Additionally, caffeine has been found to suppress the inhibitory (GABAergic) activity and modulate Neurotransmitters Dopamine GABA receptors. Studies have also found that modulating these neurotransmitters leads to neurobehav- Glutamate ioral effects. The linkage between the modulatory role of caffeine on neurotransmitters and neurobehav- GABA ioral effects has not been fully discussed. The purpose of this review is to discuss in detail the role of neurotransmitters in the effects of caffeine on neurobehavioral disorders. Ó 2020 The Author. Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
    [Show full text]
  • Effects of Maresin 1, an Omega-3 Fatty Acid-Derived Lipid Mediator, on Adipose Tissue and Liver Function in Obesity [Tesis Docto
    Facultad de Farmacia y Nutrición Effects of Maresin 1, an omega-3 fatty acid-derived lipid mediator, on adipose tissue and liver function in obesity Efectos de Maresina 1, un mediador lipídico derivado de los ácidos grasos omega-3, en la función del tejido adiposo y el hígado en obesidad Laura Laiglesia González Pamplona, 2017 Facultad de Farmacia y Nutrición Memoria presentada por Dña. Laura Laiglesia González para aspirar al grado de Doctor por la Universidad de Navarra. Fdo. Laura Laiglesia González El presente trabajo ha sido realizado bajo nuestra dirección en el Departamento de Ciencias de la Alimentación y Fisiología de la Facultad de Farmacia y Nutrición de la Universidad de Navarra y autorizamos su presentación ante el Tribunal que lo ha de juzgar. VºBº Directora VºBº Co-Directora María Jesús Moreno Aliaga Silvia Lorente Cebrián Este trabajo ha sido posible gracias a la financiación de diversas entidades: Gobierno de España (Ministerio de Economía, Industria y Competitividad) [BFU2012-36089 y BFU2015-65937-R], Gobierno de Navarra (Departamento de Salud) [67-2015], Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (CIBERObn) Instituto de Salud Carlos III (ISCIII) [CB12/03/30002], Centro de Investigación en Nutrición (Universidad de Navarra). Beca predoctoral 2013-2017: La investigación que ha dado lugar a estos resultados ha sido impulsada por la Obra Social "la Caixa” y la Asociación de Amigos de la Universidad de Navarra. Acknowledgements Me gustaría expresar mi agradecimiento a esas personas que han hecho posible la realización de este trabajo durante los últimos cuatro años, hasta aquellos que me han escuchado a pesar de no entender muy bien que es lo que estaba haciendo.
    [Show full text]